Completed PHASE4 INTERVENTIONAL 3-arm NCT00464308

A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg

The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)

Sponsor: Janssen-Cilag Pty Ltd

Updated 6 times since 2017 Last updated: Apr 2, 2014 Started: Nov 30, 2006 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Gastro-oesophageal Reflux, this trial is completed. The trial is conducted by Janssen-Cilag Pty Ltd and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag Pty Ltd

Data source: Janssen-Cilag Pty Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belconnen, Australia , Bondi Junction, Australia , Brookvale, Australia , Browns Plains, Australia , Campbelltown, Australia , Campsie, Australia , Caringbah, Australia , Castle Hill, Australia , Charlestown, Australia , Dapto, Australia and 15 more locations